Literature DB >> 7016396

Furosemide kinetics and dynamics after kidney transplant.

D E Smith, J G Gambertoglio, F Vincenti, L Z Benet.   

Abstract

We examined differences between responder (R) (40 to 80 mg/day) and nonresponder (NR) (greater than or equal to 120 mg/day) patients after kidney transplant with respect to furosemide kinetics and dynamics. Nonresponders had reduced plasma clearance (NR 64 +/- 21.4 and R 105 +/- 23 ml/min, two-sample t test; p less than 0.05), renal clearance (NR 18.4 +/- 8.1 and R 47.1 +/- 11.0 ml/min; p less than 0.005), and renal clearance to creatinine clearance ratio (NR 0.43 +/- 0.15 and R 0.80 +/- 0.07; p less than 0.005). Half-life rose in the nonresponders (NR 130 +/- 13 and R 87.6 +/- 16.3 min; p less than 0.005). There was no difference between groups with respect to nonrenal clearance, extent of availability, volume of distribution steady state, and the fraction of the dose excreted unchanged in the urine after intravenous administration. These results suggest that nonresponders have less ability to secrete furosemide into tubular fluid as well as less ability to respond to drug.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7016396     DOI: 10.1038/clpt.1981.134

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

1.  Response to furosemide during dehydration with and without naproxen pretreatment of kidney donors and renal transplant recipients.

Authors:  P A Sjöström; B G Odlind; M Hammarlund-Udenaes
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part II).

Authors:  L L Ponto; R D Schoenwald
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

3.  The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease.

Authors:  J Kraan; J H Jonkman; G H Koëter; C H Gips; P E de Jong; T W van der Mark; I Ekman; R A de Zeeuw
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Pharmacokinetics of theophylline and enprofylline in patients requiring a high or low dose of theophylline.

Authors:  L C Laursen; N Johannesson; B Weeke
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  Pharmacokinetics of enprofylline in patients with impaired renal function after a single intravenous dose.

Authors:  E Lunell; O Borgå; R Larsson
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

6.  Plasma protein binding of furosemide in kidney transplant patients.

Authors:  D E Smith; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1982-12

7.  Pharmacokinetics of enprofylline in healthy elderly subjects.

Authors:  E Lunell; O Borgå
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 8.  The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients.

Authors:  A Bodenham; M P Shelly; G R Park
Journal:  Clin Pharmacokinet       Date:  1988-06       Impact factor: 6.447

9.  Effects of probenecid on enprofylline kinetics in man.

Authors:  O Borgå; R Larsson; E Lunell
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

10.  Biotransformation of furosemide in kidney transplant patients.

Authors:  D E Smith; L Z Benet
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.